| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5577986 | The Journal of Pain | 2017 | 11 Pages |
Abstract
In a pilot randomized trial comparing a prescription opioid taper support intervention to usual care, lower opioid doses and pain severity ratings were observed at 22Â weeks in both groups. The groups did not differ significantly at 22Â weeks in opioid dose or pain severity, but the taper support group improved significantly more in pain interference, pain self-efficacy, and perceived opioid problems. These results support the feasibility and promise of this opioid taper support intervention.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Mark D. Sullivan, Judith A. Turner, Cory DiLodovico, Angela D'Appollonio, Kari Stephens, Ya-Fen Chan,